The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Adaptive phase 2/3 study of EIK1001, a TLR7/8 dual agonist, in combination with pembrolizumab, as first-line therapy in participants with advanced melanoma (TeLuRide-006).
 
Bernardo Rapoport
Consulting or Advisory Role - Acino Pharma South Africa; Astra-Zeneca South Africa; Janssen; MSD South Africa
 
Diwakar Davar
Stock and Other Ownership Interests - mBiomics; Zola
Honoraria - ACM Biolabs; Arcus Biosciences; Ascendis Pharma; Castle Biosciences; Clinical Care Options (CCO); Gerson Lehrman Group; GlaxoSmithKline; Immunocore; Medical Learning Group; Merck; Regeneron; Replimune; TriSalus Life Sciences; Xilio Therapeutics
Consulting or Advisory Role - ACM Bio; Ascendis Pharma; Clinical Care Options; Gerson Lehrman Group; Replimune; TriSalus Life Sciences; Xilio Therapeutics
Speakers' Bureau - Castle Biosciences
Research Funding - Arcus Biosciences; CellSight Technologies; Checkmate Pharmaceuticals; GlaxoSmithKline; Merck; Merck; Zucero Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Application No.: 63/124,231; Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy
 
Jan-Christoph Simon
Consulting or Advisory Role - Almirall; Incyte; Johnson & Johnson; Lilly; Novartis
Travel, Accommodations, Expenses - Abbvie; Almirall
 
Oliver Bechter
No Relationships to Disclose
 
Stephane Dalle
Employment - Sanofi Pasteur (I)
Stock and Other Ownership Interests - Sanofi (I)
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); MSD (Inst); Regeneron (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - TRIM24 regulation pending patent (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD
 
Yin Wu
Honoraria - Bristol-Myers Squibb; Sun Pharma
Other Relationship - Consulting for E15 VC and Boxer Capital Management
 
Daniel Brungs
Honoraria - AstraZeneca; Medisun; MSD
Consulting or Advisory Role - AstraZeneca
 
Anna Maria Di Giacomo
Consulting or Advisory Role - Bristol-Myers Squibb/Medarex; Immunocore; Immunocore; MSD Oncology; Pierre Fabre; Sun Pharma
Travel, Accommodations, Expenses - Pierre Fabre
 
Hanna Eriksson
Honoraria - Bristol-Myers Squibb (Inst); Novartis/Pfizer (Inst); Pierre Fabre (Inst)
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Immunocore (Inst); Johnson & Johnson (Inst); Pierre Fabre (Inst)
 
Peter Mohr
Honoraria - Bristol-Myers Squibb; Delcat; Immunocore; Merck Sharp & Dohme; Novartis; Pierre Fabre; Regeneron; Sanofi; Sun Pharma Advanced Research Company
Consulting or Advisory Role - Bristol-Myers Squibb; Delcath Systems; Merck Sharp & Dohme; Novartis; Pierre Fabre; Regeneron; Sanofi; Sun Pharma
Speakers' Bureau - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; Sanofi; Sun Pharma
Research Funding - Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Novartis Deutschland LTd (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sun Pharma
 
Rossanna Pezo
Honoraria - Gilead Sciences; Merck; Novartis Canada Pharmaceuticals Inc; Pfizer/EMD Serono; Seagen
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; EMD Serono; Gilead Sciences; Lilly; Merck; Novartis Canada Pharmaceuticals Inc; Pfizer; Roche; Sanofi
Speakers' Bureau - Novartis Canada Pharmaceuticals Inc
Research Funding - Merck (Inst); Novartis (Inst); Pfizer (Inst)
 
Egle Ramelyte
Stock and Other Ownership Interests - Lilly; Novo Nordisk
Honoraria - BMS GmbH & Co. KG; Galderma; Lilly; MSD; Pierre Fabre; Regeneron; Sanofi
Consulting or Advisory Role - Amgen; Kyowa Kirin International; Pierre Fabre; Sanofi/Regeneron
Speakers' Bureau - BMS GmbH & Co. KG; MSD; Sanofi/Regeneron
Research Funding - Amgen (Inst); Sanofi/Regeneron (Inst); Sun Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Contribution to UpToDate chapter update for Superficial acitic porokeratosis.
Travel, Accommodations, Expenses - Amgen; Pierre Fabre; Sanofi
 
Gareth Rivalland
Employment - Harbour Cancer and Wellness
Leadership - Harbour Cancer and Wellness
Consulting or Advisory Role - AstraZeneca
Travel, Accommodations, Expenses - Roche
 
Toshifumi Hoki
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Muaz Sadeia
Employment - Eikon Therapeutics
Stock and Other Ownership Interests - Eikon Therapeutics; Sutro Biopharma
 
Yayan Zhang
Employment - Eikon Therapeutics
Stock and Other Ownership Interests - Eikon Therapeutics
 
Etah Kurland
Employment - Eikon Therapeutics
Stock and Other Ownership Interests - Eikon Therapeutics
 
Alexander Eggermont
Leadership - Sairopa BV
Stock and Other Ownership Interests - IO Biotech; IO Biotech (Inst); Sairopa BV; Sairopa BV (Inst); Skyline BV; Skyline Diagnostics (Inst)
Honoraria - Agenus; Bioinvent; BioNTech; Boehringer Ingelheim; Brenus Pharma; Catalym; Egle; Eurobio; Imcheck Therapeutics; Immatics; IO Biotech; Merck&Co., Inc./MSD; Oncolytics; Pfizer; Pierre Fabre; QBiotics; Regeneron; Sairopa BV; Secaarna; Skyline Diagnostics; Thermosome; Trained Immunity
Consulting or Advisory Role - Agenus; Bioinvent; BioNTech; Boehringer Ingelheim; Brenus Pharma; Catalym; Egle; Eurobio; Imcheck Therapeutics; Immatics; IO Biotech; Merck & Co., Inc./MSD; Oncolytics; Pfizer; Pierre Fabre; QBiotics; Regeneron; Sairopa BV; Secaarna; Skyline Diagnostics; Thermosome; Trained Immunity